Sanjar Alam

Sanjar Alam

Auto-generated profile, based on publicly available information

Sanjar Alam

Department of Pharmaceutics, R.V. Northland Institute, Dadri, Gautam Budh Nagar-201314, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Asian Journal of Chemistry
Verified
Journal Article
Open access
PDF file
SSSuryadev Sharma
Suryadev Sharma
SASanjar Alam
Sanjar Alam
DNDheeraj Nagpal
Dheeraj Nagpal
Posaconazole, an antifungal for invasive infections, requires liposomal formulation to overcome poor solubility and bioavailability, making robust analytical methods essential to ensure quality despite interference from excipients. The aim was to develop and validate a reverse-phase HPLC method for the quantification of posaconazole in a liposomal formulation, utilizing Design Expert software. This method was developed to ensure consistency and reliability as per the ICH guidelines. Chromatographic separation was carried out using a reverse-phase HPLC system assembled with a C18 (ODS) column (150 × 4.6 mm, 3.5 µm). A mixture of methanol and buffer in a 70:30 (v/v) ratio served as the mobile phase, with a flow rate maintained at 1 mL/min. A Quality by design (QbD) approach was employed to optimize key chromatographic conditions, including the ratio of the mobile phases, pH and rate of mobile phase flow. The validation of the developed method was done based on linearity, accuracy, precision, sensitivity, specificity and robustness. The optimized RP-HPLC method showed a linear response with a correlation coefficient (r2) of 0.9994 across the concentration range of 800-1200 µg/mL, ensuring accurate quantification of posaconazole in liposomal formulation. Precision studies demonstrated low relative standard deviations (RSD), with intra-day precision of 0.12% and inter-day precision ranging from 0.36% to 0.39%. The accuracy of the method was 98.4% to 99.4%, confirming its reliability for routine use. Ruggedness testing yielded consistent results from two analysts, with RSD values of 1.38% and 1.42%, indicating the reliability and robustness of the method. Specificity testing confirmed that the method can accurately quantify posaconazole in the presence of formulation excipients, with no interference observed. Furthermore, forced degradation stability studies revealed the stability-indicating ability of the method in terms of a clear distinction between the drug and subsequent degradation products. Based on results, this validated method provides a reliable tool for ensuring the consistent quality and therapeutic efficacy of posaconazole liposomal formulation.

1 February 2021 in International Journal of Biology Pharmacy and Allied Sciences
Verified
Journal Article
Open access
JDJagdeep Singh Dua
Jagdeep Singh Dua
RRRihan Raza
Rihan Raza
AMAshu Mittal
Ashu Mittal
PKPuspendra Kumar
Puspendra Kumar
SASanjar Alam
Sanjar Alam
ABAshutosh Badola
Ashutosh Badola

1 June 2024 in Anti-Infective Agents
Verified
Journal Article
Closed access
PDF file
SASwamita Arora
Swamita Arora
Mohit AgrawalMohit Agrawal
Mohit Agrawal
KSKantrol Kumar Sahu
Kantrol Kumar Sahu
SASanjar Alam
Sanjar Alam
WAWasim Akram
Wasim Akram
HCHema Chaudhary
Hema Chaudhary
Background: The Toll-like receptor-3 (TLR3) ligand Poly(I:C) has been shown to induce a viral aggravation of severe asthma by identifying double-stranded RNA (dsRNA). This study aimed to evaluate the therapeutic role of the TLR3/dsRNA complex inhibitor-calbiochem compound in the treatment of Poly(I:C)-induced viral asthma exacerbations through the ovalbu-min-induced asthma model in Swiss albino mice. Methods: Poly(I:C) and Ovalbumin drugs were injected in mice to sensitize (i.p. on 0, 7, and 14th day) and challenge (i.n. on the 21st and 22nd days). In contrast, the treatment drug TLR3/dsRNA complex inhibitor-calbiochem was given on the 21st and 22nd days intraperitoneally within the study period. In-vivo measurements were carried out in BALF and serum for pro-inflammatory cytokines, inflammatory leukocyte counts, lactate dehydrogenase (LDH) and nitrite levels, lungs/body weight index, and lung tissue histopathology using H and E staining in mice airways. Results: High levels of cytokines (NF-κB, IL-1β, IL-5, RANTES, MIP-2, and MCP-1) are seen in groups exposed to OVA and Poly (I:C). Further, inflammatory leukocyte cell counts, lung-body weight (LW/BW) index, airway hyperresponsiveness (AHR), and lung tissue damage sug-gest exacerbations in mice airways. On the other hand, TLR3/dsRNA complex inhibitor-calbio-chem and dexamethasone significantly reversed these changes toward normal levels. Conclusions: These results suggest that the novel compound TLR3/dsRNA complex inhibitor-calbiochem has a better therapeutic role than dexamethasone for managing inflammatory char-acteristics in asthmatic mice lungs and is a potent target for viral asthma exacerbations